Abstract
Purpose Estimate the clinical and economic benefits of lenzilumab plus standard of care (SOC) compared with SOC alone in the treatment of hospitalized COVID-19 patients from the National Health Service (NHS) England perspective.
Methods A cost calculator was developed to estimate the clinical benefits and costs of adding lenzilumab to SOC in newly hospitalized COVID-19 patients over 28 days. The LIVE-AIR trial results informed the clinical inputs: failure to achieve survival without ventilation (SWOV), mortality, time to recovery, intensive care unit (ICU) admission, and invasive mechanical ventilation (IMV) use. Base case costs included drug acquisition and administration for lenzilumab and remdesivir and hospital resource costs based on level of care required. Clinical and economic benefits per weekly cohort of newly hospitalized patients were also estimated.
Results In all populations examined, specified clinical outcomes were improved with lenzilumab plus SOC over SOC treatment alone. In a base case population aged <85 years with C-reactive protein (CRP) <150 mg/L, with or without remdesivir, adding lenzilumab to SOC was estimated to result in per-patient cost savings of £1,162. In a weekly cohort of 4,754 newly hospitalized patients, addition of lenzilumab to SOC could result in 599 IMV uses avoided, 352 additional lives saved, and over £5.5 million in cost savings. Scenario results for per-patient cost savings included: 1) aged <85 years, CRP <150 mg/L, and receiving remdesivir (£3,127); 2) Black patients with CRP <150 mg/L (£9,977); and 3) Black patients from the full population (£2,369). Conversely, in the full mITT population, results estimated additional cost of £4,005 per patient.
Conclusion Findings support clinical benefits for SWOV, mortality, time to recovery, time in ICU, time on IMV, and ventilator use, and an economic benefit from the NHS England perspective when adding lenzilumab to SOC for hospitalized COVID-19 patients.
Competing Interest Statement
AK, EJ, DC, MA are employees of Humanigen Inc. AZ, KT, ANP, RKT, MT are employees of EVERSANA which received funding from Humanigen Inc. to conduct this study.
Clinical Trial
NCT04351152
Funding Statement
This work was supported by Humanigen Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The current budget impact model did not require IRB oversight or approval. The LIVE-AIR trial on which the clinical efficacy was based was conducted in accordance with the Good Clinical Practice guidelines of the International Council for Harmonization E6 and the principles of the Declaration of Helsinki. The protocol was approved by Advarra, the central institutional review board. The ID number was Pro00043147. Additionally, local ethics committees at Mayo Clinic and the University of Southern California approved the protocol. Participants provided written informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
Abbreviations
- AE
- adverse event
- CMA
- Conditional Marketing Authorisation
- COVID-19
- Coronavirus Disease 2019
- CPI
- consumer price inflation
- CRP
- C-reactive protein
- EUA
- emergency use authorization
- EUR
- euros
- FDA
- Food and Drug Administration
- GBP
- pound sterling
- GM-CSF
- granulocyte-macrophage colony-stimulating factor
- ICU
- intensive care unit
- IL-6
- interleukin-6
- IMV
- invasive mechanical ventilation
- MHRA
- Medicines and Healthcare products Regulatory Agency
- mITT
- modified intent-to-treat
- NHS
- National Health Service
- NICE
- National Institute for Health and Care Excellence
- NNT
- number needed to treat
- ONS
- Office of National Statistics
- SOC
- standard of care
- SpO2
- oxygen saturation
- SWOV
- survival without ventilation
- UK
- United Kingdom
- US
- United States.
